2.
继发性扩张型心肌病患者临床资料比较结果
Comparison of clinical data in Secondary DCM
| Parameter | LVRR组(n=92) | 未LVRR组(n=118) | P |
| a: Mean ± Standard deviation, b: Number/%, *: The original value is transformed by logarithm. LVRR: left ventricular reverse remodeling, BMI: Body Mass Index, NT-proBNP: N-teminal probrain natriuretic peptide, RDW: Red cell distribution width, LVEDD: End-diastolic diameter, LVEF: Left ventricular ejection fration, ACEI: Angiotensin converting enzyme inhibitor, ARB: Angiotensin Ⅱ recptor antagonist. | |||
| Agea (years) | 50.70±19.95 | 48.08±17.70 | 0.331 |
| Male [case/(%)] | 71/(77.17) | 88/(74.57) | 0.663 |
| BMIa (kg/m2) | 23.75±2.84 | 23.76±2.68 | 0.964 |
| Smokeb | 28 | 39 | 0.687 |
| Heavy drinkingb | 5 | 15 | 0.075 |
| NYHA classification | |||
| Ⅰb | 8 | 12 | 0.718 |
| Ⅱb | 18 | 28 | 0.469 |
| Ⅲb | 35 | 44 | 0.911 |
| Ⅳb | 31 | 34 | 0.448 |
| Heart failure coursea (month) | 20.53±17.01 | 25.61±20.78 | 0.050 |
| Hypertensionb | 42 | 62 | 0.322 |
| Diabetesb | 27 | 31 | 0.621 |
| Ventricular tachyarrhythmiasb | 15 | 25 | 0.371 |
| Etiological treatmentb | 75 | 52 | < 0.001 |
| Baseline data | |||
| Systolic blood pressurea (mmHg) | 122.08±25.72 | 117.61±15.78 | 0.129 |
| Absence of electrolyte disbalanceb | 22 | 42 | 0.068 |
| RDWa (%) | 13.86±0.73 | 14.14±1.38 | 0.088 |
| Hemoglobina (g/L) | 129.67±61.87 | 215.30±45.55 | 0.158 |
| Plateleta (109/L) | 227.13±61.87 | 215.30±45.55 | 0.134 |
| Albumina (g/L) | 36.22±3.12 | 35.54±4.46 | 0.215 |
| Uric Acida (mmol/L) | 453.42±80.06 | 444.71±97.67 | 0.516 |
| Creatinine a (μmol/L) | 91.32±29.20 | 95.45±45.49 | 0.438 |
| Glomerular filtration ratea (%) | 85.79±12.97 | 82.87±13.56 | 0.130 |
| Cholesterola (mmol/L) | 4.84±0.67 | 4.65±1.02 | 0.128 |
| Triglyceridea (mmol/L) | 1.58±0.38 | 1.66±0.61 | 0.262 |
| Low density lipoproteina (mmol/L) | 4.31±0.80 | 4.16±1.04 | 0.226 |
| NT-proBNPa* (pg/mL) | 3.33±0.65 | 3.39±0.41 | 0.402 |
| Troponin Ia (ng/mL) | 0.448±0.71 | 0.296±0.64 | 0.113 |
| LVEDDa (mm) | 61.77±4.85 | 62.90±5.49 | 0.126 |
| LVEFa (%) | 32.38±7.47 | 30.53±10.19 | 0.151 |
| Discharge medication (Number/%) | |||
| ACE/ARBb | 75/(81.52) | 84/(71.18) | 0.083 |
| β-Blokerb | 72/(78.26) | 85/(72.03) | 0.221 |
| Spirolactoneb | 85/(92.39) | 106/(89.83) | 0.521 |
| Follow-up data | |||
| LVEDDa (mm) | 48.73±6.89 | 60.80±5.32 | < 0.001 |
| LVEFa (%) | 48.13±7.36 | 38.22±9.87 | < 0.001 |
| Mean exercise tolerance (MET)a | 6.01±1.09 | 3.30±0.70 | < 0.001 |